Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609790 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
A Phase 2 study of Glioblastoma and Recurrent Glioblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
- 20
- Study locations
NCT01609790 is a Phase 2 study of Glioblastoma and Recurrent Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 137 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01609790, a Phase 2 study of Glioblastoma and Recurrent Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
- 20
- Study locations
Study Summary
This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back (recurrent). Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and interfere with the ability of tumor cells to grow and spread. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with trebananib is more effective than bevacizumab alone in treating brain tumors.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
- OTHER Placebo Administration
- OTHER Pharmacological Study
- BIOLOGICAL Trebananib
Study Locations (20)
California
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mills-Peninsula Medical Center - Burlingame
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Sutter Cancer Research Consortium - Novato
- Saint Joseph Hospital - Orange - Orange
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- California Pacific Medical Center-Pacific Campus - San Francisco
- Sutter Solano Medical Center/Cancer Center - Vallejo
Alaska
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Arizona Oncology-Deer Valley Center - Phoenix
- Arizona Oncology Services Foundation - Scottsdale
- Arizona Oncology Associates-West Orange Grove - Tucson
Colorado
- Poudre Valley Hospital - Fort Collins
Connecticut
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2012-06-04 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609790
The ClinicalTrials.gov registry entry for NCT01609790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (27% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01609790 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT01609790 about?
NCT01609790 is a clinical study titled "Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors". This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back (recurrent). Immunotherapy with monoclonal antibodies, such as bevacizumab, may ...
What is the current status of trial NCT01609790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2012-06-04. Estimated completion is 2022-05-20.
What conditions does trial NCT01609790 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm.
What interventions are being tested in trial NCT01609790?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Placebo Administration (OTHER), Pharmacological Study (OTHER), Trebananib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01609790?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01609790 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.